Other TTP-directed treatments include daratumumab [75], an anti-CD38 antibody, and bortezomib [76], a protease inhibitor, in patients with continuous ADAMTS13 deficiency and persistent presence of anti-ADAMTS13 inhibitors despite adequate anti-CD20 inhibition. The gene discussed is CD38; the disease is thrombotic thrombocytopenic purpura.